REG - BioVentix PLC - Director/PDMR Shareholding

BioventixAnnouncement

25/04/2023 10:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230425:nRSY3901Xa&default-theme=true

RNS Number : 3901X  BioVentix PLC  25 April 2023

Bioventix plc

 

("Bioventix" or "the Company")

 

Director Dealing

 

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that the Company was notified on 24 April 2023
that on 24 April 2023 Bruce Hiscock, Chief Financial Officer of the Company,
purchased a total of 11 ordinary shares of 5 pence each in the Company
("Ordinary Shares"), at an average price of 3,823 pence per Ordinary Share
(the "Purchase"). The Ordinary Shares were purchased under a dividend
reinvestment plan ("DRIP").

 

Following the Purchase, Bruce Hiscock has a beneficial interest in 761
Ordinary Shares, representing approximately 0.01 per cent. of the issued share
capital of the Company.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details.

 

 

For further information please contact:

 

 Bioventix plc                                      Tel: 01252 728 001

 Peter Harrison           Chief Executive Officer

 finnCap Ltd                                        Tel: 020 7220 0500

 Geoff Nash/Simon Hicks   Corporate Finance

 Alice Lane               ECM

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Bruce Hiscock
 2.  Reason for the Notification
 a)  Position/status                                              Chief Financial Officer
 b)  Initial notification/Amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Bioventix Plc
 b)  LEI                                                          213800225MHX7LZQY108
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of 5 pence each
     Identification code                                          GB00B4QVDF07
 b)  Nature of the transaction                                    Purchase of Ordinary Shares
 c)  Price(s) and volume(s)                                       11 Ordinary Shares

                                                                  3,823 pence
 d)  Aggregated information:                                      Purchase of 11 Ordinary Shares at 3,823 pence each

     ·     Aggregated volume

     ·     Price
 e)  Date of the transaction                                      24 April 2023
 f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEANLSADLDEEA